Preemptive Analgesia Following Uterine Artery Embolization

This study has been terminated.
(Subjects did not meet inclusion criteria)
Sponsor:
Information provided by (Responsible Party):
Antoun Nader, Northwestern University
ClinicalTrials.gov Identifier:
NCT01555073
First received: October 14, 2011
Last updated: September 11, 2014
Last verified: September 2014
Results First Received: September 11, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Double Blind (Subject, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Uterine Fibroids
Uterine Artery Embolization
Interventions: Drug: pregabalin/celecoxib
Drug: pregabalin/placebo
Drug: celecoxib/placebo
Drug: Placebo group

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Pregabalin/Celecoxib Group

pregabalin/celecoxib twice a day for 13 days.

pregabalin/celecoxib: pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.

Pregabalin/Placebo Group

pregabalin/placebo twice a day for 13 days.

pregabalin/placebo: pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.

Celecoxib/Placebo Group

celecoxib/placebo twice a day for 13 days.

celecoxib/placebo: celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.

Placebo Group

Placebo group, two placebo tablets day of surgery and twice a day for 13 days

Placebo group: Placebo group, two placebo tablets day of surgery and twice a day for 13 days


Participant Flow:   Overall Study
    Pregabalin/Celecoxib Group     Pregabalin/Placebo Group     Celecoxib/Placebo Group     Placebo Group  
STARTED     7     3     7     6  
COMPLETED     6     1     7     1  
NOT COMPLETED     1     2     0     5  
Lost to Follow-up                 1                 2                 0                 5  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Baseline Analysis population description

Reporting Groups
  Description
Pregabalin/Celecoxib Group

pregabalin/celecoxib twice a day for 13 days.

pregabalin/celecoxib: pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.

Pregabalin/Placebo Group

pregabalin/placebo twice a day for 13 days.

pregabalin/placebo: pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.

Celecoxib/Placebo Group

celecoxib/placebo twice a day for 13 days.

celecoxib/placebo: celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.

Placebo Group

Placebo group, two placebo tablets day of surgery and twice a day for 13 days

Placebo group: Placebo group, two placebo tablets day of surgery and twice a day for 13 days

Total Total of all reporting groups

Baseline Measures
    Pregabalin/Celecoxib Group     Pregabalin/Placebo Group     Celecoxib/Placebo Group     Placebo Group     Total  
Number of Participants  
[units: participants]
  7     3     7     6     23  
Age  
[units: participants]
         
<=18 years     0     0     0     0     0  
Between 18 and 65 years     7     3     7     6     23  
>=65 years     0     0     0     0     0  
Gender  
[units: participants]
         
Female     7     3     7     6     23  
Male     0     0     0     0     0  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Post Operative Pain Control   [ Time Frame: Expected average of 12 weeks ]

2.  Secondary:   Quality of Life   [ Time Frame: Expected average of 12 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Early termination due to lost of follow-up for primary outcome at 3 months


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Antoun Nader, MD
Organization: Northwestern University, Feinberg School of Medicine
phone: 312-695-3045
e-mail: a-nader2@northwestern.edu


No publications provided


Responsible Party: Antoun Nader, Northwestern University
ClinicalTrials.gov Identifier: NCT01555073     History of Changes
Other Study ID Numbers: STU00004604
Study First Received: October 14, 2011
Results First Received: September 11, 2014
Last Updated: September 11, 2014
Health Authority: United States: Institutional Review Board